About ocular therapeutix inc. - OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
OCUL At a Glance
Ocular Therapeutix, Inc.
15 Crosby Drive
Bedford, Massachusetts 01730
| Phone | 1-781-357-4000 | Revenue | 51.95M | |
| Industry | Pharmaceuticals: Major | Net Income | -265,939,000.00 | |
| Sector | Health Technology | Employees | 325 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
OCUL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 43.755 |
| Price to Book Ratio | 4.006 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.071 |
| Enterprise Value to Sales | 31.049 |
| Total Debt to Enterprise Value | 0.048 |
OCUL Efficiency
| Revenue/Employee | 159,849.231 |
| Income Per Employee | -818,273.846 |
| Receivables Turnover | 1.695 |
| Total Asset Turnover | 0.082 |
OCUL Liquidity
| Current Ratio | 15.394 |
| Quick Ratio | 15.324 |
| Cash Ratio | 14.507 |
OCUL Profitability
| Gross Margin | 87.346 |
| Operating Margin | -519.753 |
| Pretax Margin | -511.904 |
| Net Margin | -511.904 |
| Return on Assets | -41.911 |
| Return on Equity | -54.852 |
| Return on Total Capital | -36.366 |
| Return on Invested Capital | -47.589 |
OCUL Capital Structure
| Total Debt to Total Equity | 11.763 |
| Total Debt to Total Capital | 10.525 |
| Total Debt to Total Assets | 9.489 |
| Long-Term Debt to Equity | 11.333 |
| Long-Term Debt to Total Capital | 10.14 |